Chronic Cough Trials And Focused Pulmonologist Reach Will Support Long Term Upside Potential

Catalysts

About Trevi Therapeutics

Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio for chronic cough conditions associated with fibrotic lung diseases and refractory chronic cough.

What are the underlying business or industry changes driving this perspective?

• Growing recognition of chronic cough in idiopathic pulmonary fibrosis and other interstitial lung diseases as a distinct, undertreated symptom area with no FDA approved therapies, alongside approximately 150,000 IPF patients and an estimated 228,000 non IPF ILD patients where a material subset have uncontrolled cough, positions Haduvio in a therapy class that could directly influence future revenue potential if clinical programs succeed.
• Two planned global Phase III trials in IPF related chronic cough, plus adaptive Phase IIb and Phase III work in non IPF ILD chronic cough, concentrate resources on a tightly linked physician base of pulmonologists. This can support focused commercial efforts and may have a meaningful effect on future selling costs, net margins and operating leverage.
• Parallel development of multiple chronic cough indications, including refractory chronic cough with a Phase IIb dose ranging trial, creates several potential data readouts from the same core asset. This can increase the number of possible label expansions over time and influence long term earnings power if approvals follow.
• FDA alignment at End of Phase 2 for IPF related chronic cough, including agreement on objective cough monitoring as the primary endpoint and a clear pathway to NDA, reduces regulatory uncertainty around trial design and can provide greater visibility for planning around future revenue timing and associated R&D spending.
• Approximately US$188 million in cash, cash equivalents and marketable securities at year end 2025 with an indicated runway into 2028 funds top line data across key IPF, non IPF ILD and refractory chronic cough studies. This limits near term financing pressure and can support more controlled decision making around future capital structure, share count and potential earnings per share.

Assumptions

How have these above catalysts been quantified?

• Trevi Therapeutics currently has no revenue. Analysts are forecasting revenue to reach $20.1 million by August 2029.
• Analysts are not forecasting that Trevi Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Trevi Therapeutics's profit margin will increase from 0.0% to the average US Pharmaceuticals industry of 22.1% in 3 years.
• If Trevi Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $4.4 million (and earnings per share of $0.03) by about August 2029, up from -$45.6 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 1258.3x on those 2029 earnings, up from -56.8x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 15.5x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• All of Trevi's value is currently tied to Haduvio, so any setback in the Phase III IPF-related chronic cough trials, non-IPF ILD program or RCC program, such as weaker than expected efficacy, higher placebo effects or safety findings, could materially limit potential adoption and put future revenue at risk.
• The development plan depends on multiple global trials running in parallel, label-enabling Phase I studies and regulatory meetings across several indications. Any delay in enrollment, data readouts or FDA alignment could extend timelines, increase R&D spending and weigh on near-term earnings.
• Management highlights a cash runway of approximately US$188 million into 2028 that does not fully fund the 52-week IPF Phase III trial through its 24-week efficacy readout. Further capital raising is therefore likely and could lead to higher share count growth than analysts expect, which would pressure future earnings per share.
• The target patient groups are defined by chronic cough in fibrotic lung diseases. Future IPF or ILD therapies, antifibrotic combinations or other chronic cough drugs could emerge and compete for the same pulmonologist base, which could limit Haduvio's pricing power and reduce long-term net margins.
• Regulatory and labeling outcomes remain uncertain, including questions around orphan drug designation, any potential dependence language or drug-drug interaction requirements. A more restrictive label for Haduvio than investors expect could cap physician use and constrain revenue and earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $26.18 for Trevi Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $36.0, and the most bearish reporting a price target of just $20.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $20.1 million, earnings will come to $4.4 million, and it would be trading on a PE ratio of 1258.3x, assuming you use a discount rate of 7.1%.
• Given the current share price of $18.25, the analyst price target of $26.18 is 30.3% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.